SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 245 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,136,875 | -21.6% | 42,500 | 0.0% | 0.06% | -15.3% |
| Q1 2024 | $1,449,675 | +17.9% | 42,500 | 0.0% | 0.07% | +22.0% |
| Q4 2023 | $1,229,950 | +5.0% | 42,500 | 0.0% | 0.06% | -6.3% |
| Q3 2023 | $1,171,725 | -8.3% | 42,500 | 0.0% | 0.06% | +31.2% |
| Q2 2023 | $1,277,550 | -17.0% | 42,500 | 0.0% | 0.05% | -15.8% |
| Q1 2023 | $1,539,775 | +1.6% | 42,500 | 0.0% | 0.06% | +7.5% |
| Q4 2022 | $1,515,975 | +36.1% | 42,500 | +29.2% | 0.05% | +20.5% |
| Q3 2022 | $1,114,000 | -97.6% | 32,900 | -98.9% | 0.04% | -94.6% |
| Q2 2022 | $46,562,000 | +4280.2% | 2,951,096 | +8869.9% | 0.82% | +2305.9% |
| Q1 2022 | $1,063,000 | +10.8% | 32,900 | 0.0% | 0.03% | +9.7% |
| Q4 2021 | $959,000 | +9.4% | 32,900 | 0.0% | 0.03% | +10.7% |
| Q3 2021 | $877,000 | -13.4% | 32,900 | 0.0% | 0.03% | -15.2% |
| Q2 2021 | $1,013,000 | – | 32,900 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |